<DOC>
	<DOCNO>NCT00417885</DOCNO>
	<brief_summary>To assess progression-free survival combination dose determine Phase 1 portion study , safety sunitinib combine exemestane patient metastatic locally-recurrent , unresectable breast cancer .</brief_summary>
	<brief_title>A Clinical Trial Assessing Efficacy Safety Sunitinib Exemestane Patients With ER Estrogen Receptor + and/or PgR Progesterone Receptor + Breast Cancer</brief_title>
	<detailed_description>The trial terminate prematurely August 28 , 2008 due inability recruit plan number subject order provide meaningful efficacy data . There safety concern regard study decision terminate trial .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>At least 18 year age Estrogen and/or progesterone receptor positive adenocarcinoma breast evidence 1 ) unresectable 2 ) locally recurrent , 3 ) metastatic disease Postmenopausal ECOG [ Eastern Cooperative Oncology Group ] &lt; /=1 Evaluable ( e.g bone disease allow ) Measurable disease [ RECIST ( Response Evaluation Criterion Solid Tumors ) ] HER2 [ Human Epidermal Growth factor Receptor 2 ] positive disease previously treat herceptin Any prior antiangiogenic therapy , endocrine cytotoxic anticancer therapy metastatic disease set Radiation therapy within 2 week first study treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>